Quanterix (QTRX) Reaches $17.05 After 4.00% Up Move; Esperion Therapeutics (ESPR) Shorts Up By 19.77%

April 17, 2018 - By Linda Rogers

Esperion Therapeutics Inc (NASDAQ:ESPR) had an increase of 19.77% in short interest. ESPR’s SI was 3.46 million shares in April as released by FINRA. Its up 19.77% from 2.89 million shares previously. With 653,200 avg volume, 5 days are for Esperion Therapeutics Inc (NASDAQ:ESPR)’s short sellers to cover ESPR’s short positions. The SI to Esperion Therapeutics Inc’s float is 16.27%. The stock increased 2.75% or $2.05 during the last trading session, reaching $76.54. About 475,607 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since April 17, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

The stock of Quanterix Corporation (NASDAQ:QTRX) is a huge mover today! The stock increased 6.03% or $0.97 during the last trading session, reaching $17.05. About 65,151 shares traded. Quanterix Corporation (NASDAQ:QTRX) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.The move comes after 7 months positive chart setup for the $374.03M company. It was reported on Apr, 17 by Barchart.com. We have $17.73 PT which if reached, will make NASDAQ:QTRX worth $14.96M more.

Investors sentiment decreased to 1.33 in 2017 Q4. Its down 0.34, from 1.67 in 2017Q3. It dived, as 19 investors sold Esperion Therapeutics, Inc. shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Raymond James Fincl Advisors owns 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 3,365 shares. Price T Rowe Inc Md invested in 0% or 190,087 shares. Bamco Ny holds 0% or 12,900 shares. Hall Laurie J Trustee invested in 190 shares. Victory Mngmt has 282 shares. Balyasny Asset Mgmt Ltd Liability Com owns 403,164 shares. Rhenman And Partners Asset Ab reported 3.44% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). State Of Wisconsin Invest Board owns 11,000 shares. Two Sigma Secs reported 0.01% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Quantbot Tech L P reported 354 shares stake. Wasatch reported 0.61% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Citadel Advisors Ltd Com reported 0.01% stake. Pentwater Lp invested 0.84% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). California State Teachers Retirement Sys accumulated 26,747 shares. Jpmorgan Chase & owns 82,261 shares.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $2.03 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 61 analyst reports since July 28, 2015 according to SRatingsIntel. The company was maintained on Wednesday, March 9 by JMP Securities. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, November 6 report. Needham maintained it with “Buy” rating and $25 target in Thursday, June 30 report. The firm earned “Buy” rating on Wednesday, June 29 by Citigroup. JP Morgan downgraded the shares of ESPR in report on Wednesday, June 29 to “Neutral” rating. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Sell” rating by Chardan Capital Markets on Monday, August 31. JP Morgan maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, February 21. JP Morgan has “Neutral” rating and $65 target. Cowen & Co maintained the shares of ESPR in report on Wednesday, October 18 with “Buy” rating. Needham upgraded the shares of ESPR in report on Wednesday, August 19 to “Strong Buy” rating. The rating was initiated by Lake Street on Monday, October 26 with “Buy”.

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. The company has market cap of $374.03 million. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test. It currently has negative earnings. The company??s products also comprise kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips.

Analysts await Quanterix Corporation (NASDAQ:QTRX) to report earnings on June, 18. After $-1.06 actual EPS reported by Quanterix Corporation for the previous quarter, Wall Street now forecasts -76.42% EPS growth.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts